Release Date: February 25, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Can you talk more about the conversations you've been having with carriers over additional capitated arrangements? Specifically, are we at a point yet with the Humana arrangement that you can demonstrate to payers, clinical outperformance, reduction in admissions, or other data to support more incremental adoption of those capitated programs? A: Suzanne Foster, Chief Executive Officer: We have ongoing conversations with various proposed capitated arrangements in our pipeline that are progressing well. Our relationship with Humana remains strong, and they have been very complimentary about our performance. Jason Clemens, Chief Financial Officer, added that since the last quarter, they have signed additional capitated arrangements, although not as large as the Humana deal.
Q: Can you talk more about your working capital outlook and how much cash flow improvement we can expect from your various efficiency initiatives? A: Jason Clemens, Chief Financial Officer: We are pleased with our free cash flow performance in 2024. All levers of working capital have made progress, and we expect same or better DSOs over the course of 2025. We are making demonstrable improvements in inventory management and CapEx management, which should contribute to cash flow improvement.
Q: On the Diabetes business, what are you thinking about for the contribution to 2025 guidance? A: Jason Clemens, Chief Financial Officer: For pump and pump supplies, we expect to start showing some modest growth. Regarding CGM, we are not committing to growth until we have proven it, as there are many moving pieces. We are making progress and intend to continue that for the balance of 2025.
Q: Do you still see synergies and strategic value to owning the diabetes segment? A: Suzanne Foster, Chief Executive Officer: Yes, we see potential for growth with our hospital customers and future capitated arrangements. The breadth of our portfolio and geographic reach are valuable, and if we can get diabetes performing well, it will be a winning combination.
Q: Can you talk about the changes made in the Diabetes segment, specifically the reworking of the resupply outreach program and rebuilding trust from the referral standpoint? A: Suzanne Foster, Chief Executive Officer: We started with a new leadership team and shifted the resupply business to leverage our sleep resupply operations. We have improved patient outreach and retention, and our sales team is now better aligned with our HME team to improve referral processes.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.